Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PBMs Would Be "Full Partners" With Government Under Thomas Medicare Bill

Executive Summary

Pharmaceutical benefit management companies will have the opportunity to become part of a "public-private partnership" with the federal government under Rep. Thomas' (R-Calif.) upcoming Medicare prescription drug bill.

You may also be interested in...



PBM Industry Divided On Accepting Risk Under Medicare Rx Benefit Plan

The PBM industry has not yet reached a consensus on whether PBMs should become risk-bearing entities under a Medicare drug benefit proposal.

PBM Industry Divided On Accepting Risk Under Medicare Rx Benefit Plan

The PBM industry has not yet reached a consensus on whether PBMs should become risk-bearing entities under a Medicare drug benefit proposal.

Medicare Rx Insurers Would Receive 25%-30% Subsidy Under GOP Plan

Health plans offering prescription drugs under Medicare would receive a 25%-30% effective subsidy from the government under the Medicare drug benefit bill being developed by Rep. Thomas (R-Calif.).

Related Content

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel